SFX by Ex Libris Inc.

Title:	Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model
Source:	Human Molecular Genetics [0964-6906] Tomassini, B yr:2012

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Seyer, L. "Open-label pilot study of interferon gamma-1b in Friedreich ataxia." Acta neurologica Scandinavica 132.1 (2014): 7-15.
description	2.	Lynch, David R. "Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia." Annals of Clinical and Translational Neurology (2019): 546-553.
description	3.	Kamphausen, E. "Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma." Cancer immunology and immunotherapy 59.8 (2010): 1273-1284.
description	4.	Wells, M. "IFN-γ for Friedreich ataxia: present evidence." Neurodegenerative Disease Management 5.6 (2015): 497-504.
description	5.	Marcotulli, C. "GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients." Neurological Sciences 37.3 (2016): 361-364.
description	6.	Mariotti, C. "Erythropoietin in Friedreich ataxia." Journal of neurochemistry 126.s1 (2013): 80-87.
description	7.	Wang, G. "Signal transducers and activators of transcription-1 (STAT1) regulates microRNA transcription in interferon gamma-stimulated HeLa cells." PLoS ONE 5.7 (2010).
description	8.	Pekarikova, A. "Calreticulin is a B cell molecular target in some gastrointestinal malignancies." Clinical and experimental immunology 160.2 (2010): 215-222.
description	9.	Mariotti, C. "Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial." Movement disorders 27.3 (2012): 446-449.
description	10.	Enns, William M. "Initial experience in the treatment of inherited mitochondrial disease with EPI-743." Molecular genetics and metabolism 105.1 (2011): 91-102.
description	11.	Santos, R. "Friedreich Ataxia: Molecular Mechanisms, Redox Considerations, and Therapeutic Opportunities." Antioxidants & redox signaling 13.5 (2010): 651-690.
description	12.	Shoeibi, A. "Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy." Expert opinion on investigational drugs 27.4: 349-361.
description	13.	Puccio, H. "Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia." Nature medicine 20.5 (2014): 542-547.
description	14.	Broxmeyer, Hal E. "Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration." The Journal of experimental medicine 210.2 (2013): 205-208.
description	15.	MAKIN, M. "The surgical management of Friedreich's ataxia." Annals of the Royal College of Surgeons of England 22.1 (1958): 1-10.
description	16.	Globas C, C. "The cerebellum and cognition. Intellectual function in spinocerebellar ataxia type 6 (SCA6)." Journal of Neurology 250.12 (2003): 1482-1487.
description	17.	Jen, Joanna C C. "Hereditary episodic ataxias." Annals of the New York Academy of Sciences 1142.1 (2008): 250-3.
description	18.	Gold, Leslie I. "Calreticulin: non-endoplasmic reticulum functions in physiology and disease." The FASEB journal 24.3 (2010): 665-683.
description	19.	Duerksen, Duerksen R. "A Comparison of Antibody Testing, Permeability Testing, and Zonulin Levels with Small-Bowel Biopsy in Celiac Disease Patients on a Gluten-Free Diet." Digestive Diseases and Sciences 55.4 (2010): 1026-1031.
description	20.	Celis, Peter E. "Up-regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast." Molecular Oncology 4.1 (2010): 65-89.